Volume 15, Issue 9 (February 2013)                   J Arak Uni Med Sci 2013, 15(9): 12-20 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Bashash D, Ghaffari S H, Kazerani M, Hezaveh K, Alimoghaddam K, Ghavamzadeh A. Pro-apoptotic effect of BIBR1532 on APL cell line: Induction of rapid cell death independent of progressive shortening of telomere length. J Arak Uni Med Sci. 2013; 15 (9) :12-20
URL: http://amuj.arakmu.ac.ir/article-1-1712-en.html
Professor Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences. , Shghaffari200@yahoo.com
Abstract:   (8579 Views)
Background: Since nearly 90% of patients with acute promyelocytic leukemia (APL) have high telomerase activity and significant shortened telomere length, these patients have, therefore, been suggested to be good candidates for the therapeutic intervention with telomerase inhibitors. This study was done to investigate the effects of BIBR1532, a non-nucleoside inhibitor of telomerase, on APL cells. Materials and Methods: In this experimental study, for investigating the effect of BIBR1532, NB4 leukemic cells were cultured in the presence of various concentrations of BIBR1532. Succeeding apoptosis assay, Caspase-3 activity assay, and quantitative real-time PCR were applied to examine the effect of this drug on apoptosis percenage, enzymatic activity of Caspase-3, and quantitative expression of genes mRNA involved in apoptosis. Results: The results showed that BIBR1532 induced apoptosis in NB4 cells in a dose-dependent maner. Moreover, real time PCR results showed that BIBR1532 led to a significant decrease in mRNA of Bcl-2 gene and signficant increases in transcription of Bax, PUMA, and Caspase-3. Conclusion: Since treatment with BIBR1532 could exert rapid apoptotic cell death in NB4 cells andactivate cellular apoptosis route, anti-telomerase-based therapy can regarded as a suitable strategy for APL treatment. Patients with progressive shortening of telomere length and high levels of telomerase activity are suitable candidates for treatment with telomerase inhibitors.
Full-Text [PDF 373 kb]   (2183 Downloads)    
Type of Study: Original Atricle | Subject: Oncology
Received: 2012/06/4 | Accepted: 2012/09/18

Add your comments about this article : Your username or Email:
Write the security code in the box

Send email to the article author

© 2018 All Rights Reserved | Journal of Arak University of Medical Sciences

Designed & Developed by : Yektaweb